Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Cutaneous small-vessel vasculitis

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Skin findings may mark systemic vasculitis

Necrosis, rapidly spreading purpura, haemodynamic illness, pulmonary symptoms, abdominal pain, neurological deficit or nephritic urine means the process cannot be managed as an uncomplicated skin-limited eruption.

Action: Assess sepsis and organ perfusion immediately, obtain blood cultures and urine and renal testing, photograph and biopsy active lesions when safe, and arrange same-day dermatology and organ-specialist care without waiting for outpatient autoantibodies.

Synopsis

Recognise palpable-purpuric small-vessel inflammation, separate skin-limited disease from systemic vasculitis and mimics, biopsy the correct lesions, remove triggers and escalate only persistent, ulcerating or organ-associated disease.

  • The hallmark is palpable non-blanching purpura, usually in crops on dependent lower legs; vesicles, bullae, pustules, urticarial plaques, ulcers or necrosis can occur.
  • Cutaneous small-vessel vasculitis describes a vessel pattern and distribution, not one cause; always decide whether disease is skin-limited, systemic or secondary to infection, medicine, autoimmunity or malignancy.
  • At the first assessment check observations, blood pressure, urine dip, creatinine, FBC and symptoms from lungs, kidneys, bowel and nerves before calling the eruption benign.
  • For diagnostic confirmation, ideally take two lesions less than 48 hours old: a non-necrotic purpuric papule for routine histology and an early partially blanchable macule for direct immunofluorescence.
  • Routine histology showing leukocytoclasis proves small-vessel inflammation but not its cause; IgA, complement or immunoglobulin deposition and the clinical phenotype refine classification.
  • A single mild skin-limited episode is usually managed first by removing a credible trigger, treating infection, rest, leg elevation, skin care, analgesia and compression only when arterial supply is adequate.
  • Persistent, recurrent, painful, bullous or ulcerating disease needs dermatology review; colchicine or dapsone are specialist off-label steroid-sparing choices with different renal, interaction, G6PD and blood-monitoring constraints.
  • Systemic glucocorticoid is reserved for severe skin disease or organ involvement after infection assessment; it is not routine treatment for every purpuric crop.
  • Do not inject or immunosuppress a suspected infected lesion and do not use an NSAID when nephritis, gastrointestinal bleeding, significant renal disease or cardiovascular contraindication is present.

Key red flags

Breathlessness, haemoptysis, falling oxygen saturation or bilateral infiltrates raises diffuse alveolar haemorrhage or infection and requires acute admission.

Haematuria, proteinuria, rising creatinine, oedema or hypertension suggests glomerulonephritis and needs urgent renal and vasculitis assessment.

Severe abdominal pain, gastrointestinal bleeding or guarding may represent bowel vasculitis, ischaemia, perforation or another surgical emergency.

New focal weakness, foot drop, asymmetric sensory loss, confusion or seizure indicates possible peripheral or central nervous-system vasculitis.

Retiform purpura, bullae, ulceration, necrosis, rapidly progressive pain or cold poorly perfused tissue suggests occlusion, deeper-vessel disease or severe inflammation.

Fever, hypotension, non-blanching rash and toxicity require an immediate sepsis and meningococcal pathway, not a delayed dermatology work-up.

Systemic vasculitis signal

Haematuria, breathlessness, abdominal pain, bleeding, fever, weight loss or focal neuropathy accompanying purpura moves assessment beyond skin-limited disease.

Occlusive morphology

Livedo, angulated retiform purpura, cold tissue or necrosis suggests thrombosis, embolism, cryoprotein or deeper-vessel disease rather than uncomplicated leukocytoclastic inflammation.

Investigation priorities

01
First-line observations, urine and renal profileFirst stepFirst line

Identify sepsis, hypertension and silent glomerular involvement at the initial encounter.

Management branches

First-line triageDecide skin-limited or systemic

A new non-blanching palpable eruption is identified.

  1. Record observations and blood pressure, examine lesion morphology and perfusion and ask systematically about renal, pulmonary, bowel, neurological and infectious symptoms.
  2. Perform urine dip, FBC, renal and liver tests and inflammatory markers and arrange same-day escalation for toxicity, necrosis or any organ signal.
  3. Photograph active untreated lesions and secure appropriately timed routine-histology and DIF biopsies when confirmation will alter classification.
Skin-limited first-line careRemove pressure and the driver

The patient is well, baseline organ assessment is reassuring and lesions are non-necrotic.

  1. Review and remove a credible medicine trigger safely, treat identified infection and avoid adding an unnecessary antibiotic or immunosuppressant.
  2. Use rest during painful crops, leg elevation, bland emollient, appropriate dressings and compression only after arterial adequacy is established.
  3. Offer symptom-specific analgesia, topical corticosteroid for inflammatory itch or antihistamine, then review urine and trajectory with clear return advice.

Key medicines

Colchicine for recurrent skin-limited vasculitisA common specialist off-label trial is 500 micrograms orally once daily, increasing to 500 micrograms twice daily if needed and tolerated; review response after several weeks and stop if ineffective.This indication is off-label. Reduce or avoid in renal or hepatic impairment, stop for diarrhoea or vomiting and check interactions with macrolides, azoles, ciclosporin, verapamil and statins because fatal toxicity, cytopenia and neuromyopathy can occur. Pregnancy or breastfeeding requires specialist product-specific review.
DapsoneSpecialists commonly start 50 mg orally once daily and may increase to 100 mg once daily according to skin response and blood safety; cutaneous small-vessel vasculitis is an off-label indication.Check G6PD activity, FBC, reticulocytes, liver and renal function before treatment and monitor FBC closely. Severe G6PD deficiency and severe anaemia are contraindications; haemolysis, methaemoglobinaemia, agranulocytosis, hepatitis and neuropathy require urgent review. Use in pregnancy only when benefit outweighs risk; breastfeeding can cause infant haemolysis and needs specialist review.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists cutaneous vasculitis informationUK causes, organ screening, supportive care and escalation options.
  • EADV diagnostic work-up position statementCurrent lesion selection, biopsy timing, DIF and proportionate systemic investigation.
  • Primary Care Dermatology Society vasculitis guidanceUK assessment, conservative care and commonly used off-label systemic regimens.
  • Dapsone 50 mg UK product informationContraindications, G6PD, blood, hepatic and methaemoglobin safety.
  • Colchicine 500 microgram UK product informationLicensed gout dosing and renal, hepatic and interaction toxicity relevant to off-label use.
  • Prednisolone 5 mg UK product informationInfection, withdrawal, metabolic and reproductive safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewUnited Kingdom
Jurisdiction